FLT3 and acute myeloid leukemia: R/R FLT3-ITD-mutated (FLT3-ITD mutation frequency 30.6%, AR 0.388) AML was confirmed, and the patient received venetoclax (VEN, 200 mg/day) combined with azacitidine (AZA, 100 mg/day, D1–7) on May 11, 2021.